IPLEX is a complex of recombinant human IGF-1 and its binding protein IGFBP-3 (rhIGF-1/rhIGFBP-3) that has been studied as a treatment for several serious medical conditions. We have out-licensed rights to Premacure AB of Sweden to develop, manufacture and commercialize IGF-1, with its natural binding protein, IGFBP-3, at lower concentrations than IPLEX for the prevention and treatment of complications of preterm birth. Premacure is currently focusing on retinopathy of prematurity. We also plan to identify licensing partners for other IPLEX development programs.
"Preclinical models demonstrate that both rhIGFBP-3 and INSM-18 interact with the IGF system to reduce tumor growth. We are not actively pursuing the development of either of these products at this time and have out licensed the rights of INSM-18 to Napo Pharmaceuticals, Inc., for diabetes and to TriAct Therapeutics Inc. for other INSM -18 indications. Due to the high cost of trials in the oncology area, we would need to identify a partner to co-develop rhIGFBP-3."
Someone is interested in using rhIGFBP-3
"The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of either an anti-IGF-1R antibody or an IGF binding protein (e.g. IGFBP3), and a small molecule IGF-1R kinase inhibitor (e.g. OSI-906). The present invention also provides a pharmaceutical composition comprising either an anti-IGF-1R antibody or an IGF binding protein (e.g. IGFBP3), and a small molecule IGF-1R kinase inhibitor (e.g. OSI-906), with a pharmaceutically acceptable carrier."